Here, we review the evidence supporting the most common gene expression signatures (MammaPrint, BluePrint, Oncotype Dx, PAM50, EndoPredict, and the Breast Cancer Index) to guide the treatment of ER+/HER2- early breast cancer from the outset. This evidence concerns the gene ESR1 and breast carcinoma.